JP2023531869A - 神経保護を誘導するための化合物及び組成物 - Google Patents

神経保護を誘導するための化合物及び組成物 Download PDF

Info

Publication number
JP2023531869A
JP2023531869A JP2022571216A JP2022571216A JP2023531869A JP 2023531869 A JP2023531869 A JP 2023531869A JP 2022571216 A JP2022571216 A JP 2022571216A JP 2022571216 A JP2022571216 A JP 2022571216A JP 2023531869 A JP2023531869 A JP 2023531869A
Authority
JP
Japan
Prior art keywords
tetramethyl
oxo
compound
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531869A5 (https=
Inventor
ジル ルビンステン
タングイ モーリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73013493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2023531869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2023531869A publication Critical patent/JP2023531869A/ja
Publication of JP2023531869A5 publication Critical patent/JP2023531869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022571216A 2020-05-20 2021-05-20 神経保護を誘導するための化合物及び組成物 Pending JP2023531869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2005138 2020-05-20
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection
PCT/FR2021/050929 WO2021234324A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection

Publications (2)

Publication Number Publication Date
JP2023531869A true JP2023531869A (ja) 2023-07-26
JP2023531869A5 JP2023531869A5 (https=) 2024-05-27

Family

ID=73013493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571216A Pending JP2023531869A (ja) 2020-05-20 2021-05-20 神経保護を誘導するための化合物及び組成物

Country Status (9)

Country Link
US (1) US12611387B2 (https=)
EP (1) EP4142703B8 (https=)
JP (1) JP2023531869A (https=)
KR (1) KR20230013116A (https=)
CN (1) CN116981449A (https=)
CA (1) CA3178633A1 (https=)
ES (1) ES2970378T3 (https=)
FR (1) FR3110393B1 (https=)
WO (1) WO2021234324A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3149773B1 (fr) 2023-06-19 2026-04-17 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm
WO2026003229A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
FR3163834A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine
FR3163835A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506378A (ja) * 2002-10-24 2006-02-23 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法
WO2009062391A1 (en) * 2007-11-02 2009-05-22 Ru-Band Lu Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia
JP2014532635A (ja) * 2011-10-31 2014-12-08 コミッサリア ア レネルジ アトミック エ オー エネルジス アルテルナティヴスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ‘Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ アセチルコリンエステラーゼ阻害剤の治療効果を増強する抗コネキシン剤の使用
US20160107982A1 (en) * 2013-05-29 2016-04-21 M2I Development Novel chemical compounds derived from normemantine and use of same in the medical field
WO2019115833A1 (fr) * 2017-12-15 2019-06-20 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506378A (ja) * 2002-10-24 2006-02-23 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン １−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法
WO2009062391A1 (en) * 2007-11-02 2009-05-22 Ru-Band Lu Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia
JP2014532635A (ja) * 2011-10-31 2014-12-08 コミッサリア ア レネルジ アトミック エ オー エネルジス アルテルナティヴスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ‘Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ アセチルコリンエステラーゼ阻害剤の治療効果を増強する抗コネキシン剤の使用
US20160107982A1 (en) * 2013-05-29 2016-04-21 M2I Development Novel chemical compounds derived from normemantine and use of same in the medical field
WO2019115833A1 (fr) * 2017-12-15 2019-06-20 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUROPHARMACOLOGY, vol. 89, JPN6025031981, 2015, pages 215 - 224, ISSN: 0005833010 *
SALABERT, A.S. ET AL.: "P-51 NEW IMAGING TOOL FOR EXPLORATION OF NEUROPHYSIOPATHOLOGICAL DISORDERS: CONCEPTION OF FLUOROETHY", ALCOHOL AND ALCOHOLISM, vol. Vol.50, Suppl_1, JPN6026013655, 2015, pages 58, ISSN: 0005833011 *

Also Published As

Publication number Publication date
ES2970378T3 (es) 2024-05-28
FR3110393A1 (fr) 2021-11-26
CN116981449A (zh) 2023-10-31
US20230270695A1 (en) 2023-08-31
US12611387B2 (en) 2026-04-28
KR20230013116A (ko) 2023-01-26
EP4142703B1 (fr) 2023-10-18
FR3110393B1 (fr) 2022-05-06
EP4142703B8 (fr) 2023-11-22
EP4142703C0 (fr) 2023-10-18
CA3178633A1 (fr) 2021-11-25
WO2021234324A1 (fr) 2021-11-25
EP4142703A1 (fr) 2023-03-08

Similar Documents

Publication Publication Date Title
JP2023531869A (ja) 神経保護を誘導するための化合物及び組成物
US9144558B2 (en) Baclofen and acamprosate based therapy of neurological disorders
ES2327521T3 (es) Procedimientos de prevencion, tratamiento y diagnostico de trastornos de la agregacion de proteinas.
JP2011518119A (ja) ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途
Easton et al. Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease
Christensen Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
US20130237556A1 (en) Berberine alkaloid as a medicament for prevention and treatment of neural disease
US20240269124A1 (en) Methods and compositions for treating neurological conditions
US10912819B2 (en) Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseases
Zaky et al. Neurodegenerative disorders: available therapies and their limitations
Straten et al. Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease
CN110545835A (zh) Caspase-1抑制及其用于预防和治疗神经病症的用途
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
RU2786476C2 (ru) Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера
Kusakari et al. CLSPCOL rescues Alzheimer’s disease mouse models
Tamanna Bio-similar drug development and accessible drugs in the market for the treatment of Alzheimer's Disease: Current status
Supasai et al. HMGB1 Box A gene therapy reverses cognitive and neuropathological features in AlCl₃/D-galactose rat model of Alzheimer's disease
ES2650175A1 (es) Tratamiento de enfermedades neurodegenerativas
Davison Investigating the Effects of FTY720 on Spatial Memory and Neuroinflammation in a Rodent Model of Alzheimer’s Disease
WO2025184834A1 (zh) 一种庚酸酯化合物及其用于制备预防和/或治疗神经退行性疾病的药物或功能食品中的用途
JP2022517734A (ja) ドンペリドン抗神経変性剤の組み合わせと使用
JP2021520412A (ja) タンパク質ミスフォールディング疾患のための療法
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406